Randomized polypill crossover trial in people aged 50 and over

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Wald, David S ^a   Morris, Joan K ^a   Wald, Nicholas J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS LOSARTAN PLUS SIMVASTATIN; HYDROCHLOROTHIAZIDE; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANKLE SWELLING; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; EVENING DOSAGE; FEMALE; FLUSHING; HUMAN; LIP SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PAIN; PATIENT COMPLIANCE; POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SWELLING; SYSTOLIC BLOOD PRESSURE; TONGUE SWELLING; TREATMENT DURATION;

AGED; AMLODIPINE; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PLACEBOS; SIMVASTATIN;

EID: 84864004299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041297     Document Type: Article

References (22)

1. Wald NJ, Law MR (2000) Formulation for the Prevention of Cardiovascular Disease. UK Patents GB008791 and GB0100548.
2. Wald NJ, Law MR, ((2003)) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326:: 1419-23.
3. The Indian Polycap Study (TIPS) ((2009)) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373:: 134151.
4. PILL Collaborative Group (2011) AN international randomised placebo-controlled trial of a four-component combination pill ("Polypill") in people with raised cardiovascular risk. PlosOne. doi:10.1371/journal.pone.0019857.
5. Soliman ES, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, et al. ((2011)) A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials12:: 3.
6. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, et al. ((2010)) A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill) on cardiovascular risk factors. Int J Clin Pract 64:: 1220-7.
7. Law MR, Wald NJ, Rudnicka AR, ((2003)) Quantifying the effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:: 1423-7.
8. Law MR, Wald NJ, Morris JK, Jordan RE, ((2003)) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326:: 1427-31.
9. Wald N, Law M, ((2009)) The Indian Polycap Study (TIPS) Lancet. 374:: 781.
10. Wald DS, Wald NJ (2011) Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. Journal of Evaluation in Clinical Practice. doi: 10.1111/j.1365-2753.2011.01637.
11. Cilla DD, Gibson DM, Whitfield LR, Sedman AJ, ((1996)) Pharmacodynamic effects and pharmacokinetics of Atorvastatin after administration to normocholeterolemic subjects in the morning and evening. J Clin Pharmacol 36:: 604-9.
12. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, et al. ((2002)) Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40:: 897-902.
13. Law MR, Morris JK, Wald NJ, ((2009)) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:: b1665.
14. Wald NJ, Simmonds M, Morris JK, ((2011)) Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One 6(5):: e18742.
15. Van Gils PF, Over EAB, Hamberg-van Reenen HH, de Wit GA, van den Berg M, et al. ((2012)) The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open 2-11 1:: e000363.
16. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, et al. ((2010)) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. DOI:10.1016/S0140-6736(10)62110-1.
17. Wald NJ, Morris JK, Law MR, ((2011)) Aspirin in the prevention of cancer. Lancet 377:: 1649.
18. Law MR, Wald NJ, Morris JK, Jordan RE, ((2003)) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326:: 1427-31.
19. Law MR, Wald NJ, Rudnicka AR, ((2003)) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 326:: 1423-7.
20. Prospective Studies Collaboration, ((2002)) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:: 1903-13.
21. Prospective Studies Collaboration, ((2007)) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 370:: 1829-39.
22. Cholesterol Treatment Trialists (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27 randomised trials. Lancet [Epub ahead of print].